|
|
Blood, 1 August 2006, Vol. 108, No. 3, pp. 1058-1064.
Prepublished online as a Blood First Edition Paper on April 18, 2006; DOI 10.1182/blood-2005-08-007377.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes
Qian Zhang,
Hong Y. Wang,
Anders Woetmann,
Puthiyaveettil N. Raghunath,
Niels Odum, and
Mariusz A. Wasik
From the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Biology, University of Copenhagen, Copenhagen, Denmark.
In this study, we demonstrated that STAT3, a well-characterized transcription factor expressed in continuously activated oncogenic form in the large spectrum of cancer types, induces in malignant T lymphocytes the expression of DNMT1, the key effector of epigenetic gene silencing. STAT3 binds in vitro to 2 STAT3 SIE/GAS-binding sites identified in promoter 1 and enhancer 1 of the DNMT1 gene. STAT3 also binds to the promoter 1 region and induces its activity in vivo. Treatment of the malignant T lymphocytes with STAT3 siRNA abrogates expression of DNMT1, inhibits cell growth, and induces programmed cell death. In turn, inhibition of DNMT1 by a small molecule inhibitor, 5-aza-2-deoxy-cytidine, and 2 DNMT1 antisense DNA oligonucleotides inhibits the phosphorylation of STAT3. These data indicate that STAT3 may in part transform cells by fostering epigenetic silencing of tumor-suppressor genes. They also indicate that by inducing DNMT1, STAT3 facilitates its own persistent activation in malignant T cells. Finally, these data provide further rationale for therapeutically targeting STAT3 in T-cell lymphomas and, possibly, other malignancies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle
NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells
Cancer Res.,
November 15, 2009;
69(22):
8611 - 8619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lal and J. S. Bromberg
Epigenetic mechanisms of regulation of Foxp3 expression
Blood,
October 29, 2009;
114(18):
3727 - 3735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Krejsgaard, C. S. Vetter-Kauczok, A. Woetmann, H. Kneitz, K. W. Eriksen, P. Lovato, Q. Zhang, M. A. Wasik, C. Geisler, E. Ralfkiaer, et al.
Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma
Blood,
June 4, 2009;
113(23):
5896 - 5904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Hino, H. Uozaki, N. Murakami, T. Ushiku, A. Shinozaki, S. Ishikawa, T. Morikawa, T. Nakaya, T. Sakatani, K. Takada, et al.
Activation of DNA Methyltransferase 1 by EBV Latent Membrane Protein 2A Leads to Promoter Hypermethylation of PTEN Gene in Gastric Carcinoma
Cancer Res.,
April 1, 2009;
69(7):
2766 - 2774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Rahnama, B. Thompson, M. Steiner, F. Shafiei, P. E. Lobie, and M. D. Mitchell
Epigenetic Regulation of E-Cadherin Controls Endometrial Receptivity
Endocrinology,
March 1, 2009;
150(3):
1466 - 1472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lal, N. Zhang, W. van der Touw, Y. Ding, W. Ju, E. P. Bottinger, St. P. Reid, D. E. Levy, and J. S. Bromberg
Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation
J. Immunol.,
January 1, 2009;
182(1):
259 - 273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Garaud, C. Le Dantec, C. Berthou, P. M. Lydyard, P. Youinou, and Y. Renaudineau
Selection of the Alternative Exon 1 from the cd5 Gene Down-Regulates Membrane Level of the Protein in B Lymphocytes
J. Immunol.,
August 1, 2008;
181(3):
2010 - 2018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Marzec, K. Halasa, M. Kasprzycka, M. Wysocka, X. Liu, J. W. Tobias, D. Baldwin, Q. Zhang, N. Odum, A. H. Rook, et al.
Differential Effects of Interleukin-2 and Interleukin-15 versus Interleukin-21 on CD4+ Cutaneous T-Cell Lymphoma Cells
Cancer Res.,
February 15, 2008;
68(4):
1083 - 1091.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|